Bladder Cancer

A combination of nivolumab (Opdivo), gemcitabine (Gemzar), and cisplatin as neoadjuvant therapy resulted in a pathologic nonmuscle-invasive rate of 66% and a pathologic complete response rate (pCR) of 49% in patients with muscle-invasive bladder cancer (MIBC), according to results from the phase 2 BLASST-1 clinical trial. Read More ›

On December 2, 2019, Merck announced that the FDA has granted priority review for its supplemental biologics license application for the anti–PD-1 agent pembrolizumab (Keytruda). If approved, the drug would be indicated as monotherapy to treat patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non–muscle-invasive bladder cancer who are ineligible for or have decided not to undergo cystectomy. Read More ›

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: